The short answer
The incretin effect is the observation that glucose taken by mouth triggers substantially more insulin secretion than an identical amount infused intravenously. The difference is caused by gut hormones, principally GLP-1 and GIP, released in response to nutrients reaching the intestine. It accounts for a majority of the insulin response to a meal.
Key facts
- Definition
- Extra insulin from oral vs IV glucose
- Principal hormones
- GLP-1 and GIP
- GLP-1 source
- L cells, distal small intestine and colon
- GIP source
- K cells, proximal small intestine
- Key property
- Glucose-dependent insulin release
- Native GLP-1 half-life
- 1-2 minutes
- Degrading enzyme
- DPP-4
The experiment that defines it
Give a person glucose by mouth and measure the insulin response. Then, on another occasion, infuse glucose intravenously at a rate that reproduces exactly the same blood glucose curve. The insulin response to the oral route is far larger. Since the glucose exposure was identical by construction, something other than glucose must be driving the difference, and that something is hormonal signalling from the gut.
Why the gut signals at all
It is anticipatory. The intestine detects nutrients arriving and signals the pancreas before the resulting glucose has fully entered the circulation. That head start allows insulin secretion to rise in step with absorption rather than lagging behind it. Intravenous glucose bypasses the intestine entirely, so none of that signalling occurs.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Glucose dependence is the safety-critical property
Incretins potentiate insulin secretion only when glucose is elevated. At normal or low glucose they do very little. This is why GLP-1 receptor agonists carry a low intrinsic risk of hypoglycaemia compared with insulin or sulfonylureas, which force insulin release regardless of glucose. It is a property of the physiology the drug class inherited, not something engineered into it.
What goes wrong in type 2 diabetes
The incretin effect is markedly reduced. The GIP arm in particular loses much of its insulinotropic potency, while the GLP-1 arm remains comparatively responsive to pharmacological doses. This asymmetry is a large part of why GLP-1 was pursued as a drug target first, and why the therapeutic role of GIP agonism remained contested long after GLP-1's was settled.
From physiology to pharmacology
Native GLP-1 is destroyed within one to two minutes by DPP-4, so the hormone itself was never usable. Every drug in this class is an attempt to keep GLP-1 receptor signalling going for longer: by blocking the DPP-4 cleavage site, by binding albumin to slow clearance, or by abandoning the peptide entirely for a small molecule the enzyme does not recognise.
Frequently asked questions
How large is the incretin effect?
It accounts for a majority of the insulin response to an oral glucose load in healthy people, which is why bypassing it intravenously produces so much less insulin.
Why do GLP-1 drugs rarely cause hypoglycaemia?
Because incretin signalling is glucose-dependent. It potentiates insulin release when glucose is high and does little when it is not.
Is the incretin effect the same as the drugs' weight effect?
No. The incretin effect describes insulin secretion. Weight reduction comes largely from delayed gastric emptying and central satiety signalling, which are separate consequences of the same receptors.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Semaglutide (CID 56843331)pubchem.ncbi.nlm.nih.gov
- RefOrforglipron: A Comprehensive Review. Int J Mol Sci 2026mdpi.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- DPP-4: Why Native Incretins Last Two MinutesDPP-4 removes two residues from GLP-1 and inactivates it within minutes. How Aib8 substitution and albumin binding defeat it, and why small molecules ignore it.
- GLP-1 Drugs Beyond Weight LossSELECT showed a 20% reduction in cardiovascular events. Heart failure, kidney and peripheral artery indications followed. What the evidence supports.
- The GIP Paradox: Why Agonism and Antagonism Both Produce Weight LossTirzepatide activates the GIP receptor. MariTide blocks it. Both produce substantial weight loss alongside GLP-1 agonism, and the field has not resolved why.
- What Is Maridebart Cafraglutide? Antibody Meets PeptideMariTide is a monoclonal antibody blocking the GIP receptor, conjugated to two GLP-1 agonists. An unusual format, and the opposite premise to tirzepatide.
- Lean Mass Loss on GLP-1 Therapy, and the BELIEVE ResultA substantial share of weight lost on GLP-1 therapy is lean mass. The BELIEVE trial cut lean loss from 7.4% to 2.9% by adding bimagrumab to semaglutide.